Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Prostate cancer

Treatment sequencing for CRPC—what do we know?

Nature Reviews Urology volume 11, pages 189–190 (2014)Cite this article

Subjects

Although multiple systemic treatment options are available for men with castration-resistant prostate cancer, there is a paucity of data regarding optimal sequencing of these drugs. A recent study suggests that cabazitaxel exerts antitumour activity in men who have been pretreated with docetaxel and abiraterone or enzalutamide.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Heidenreich, A. et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 65, 467–479 (2014).

    Article  CAS  Google Scholar 

  2. Pezaro, C. J. et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2013.11.044.

  3. de Bono, J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147–1154 (2010).

    Article  CAS  Google Scholar 

  4. Fizazi, K. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 13, 983–992 (2012).

    Article  CAS  Google Scholar 

  5. Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187–1197 (2012).

    Article  CAS  Google Scholar 

  6. Zhu, M. L. et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 70, 7992–8002 (2010).

    Article  CAS  Google Scholar 

  7. Mezynski, J. et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann. Oncol. 23, 2943–2947 (2012).

    Article  CAS  Google Scholar 

  8. Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502–1512 (2004).

    Article  CAS  Google Scholar 

  9. Guo, Z. & Qiu, Y. A new trick of an old molecule: androgen receptor splice variants taking the stage?! Int. J. Biol. Sci. 7, 815–822 (2011).

    Article  CAS  Google Scholar 

  10. Schrader, A. J. et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur. Urol. 65, 30–36 (2014).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, RWTH University Aachen, Pauwelsstrasse 30, Aachen, 52074, Germany

    Axel Heidenreich & Daniel Porres

Authors
  1. Axel Heidenreich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Porres
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Axel Heidenreich.

Ethics declarations

Competing interests

A.H. has received honoraria and research grants, and served on advisory boards for the following companies: Amgen, Astellas, Bayer AG, Ferring, IPSEN, Jansen Cilag, Pfizer, Sanofi Aventis, and Takeda. D.P. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heidenreich, A., Porres, D. Treatment sequencing for CRPC—what do we know?. Nat Rev Urol 11, 189–190 (2014). https://doi.org/10.1038/nrurol.2014.36

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2014.36

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing